Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.43 |
| ▸ | CDK9 | P50750 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27463188 | 0.88 | CCNT1 (0.40) | CCNT1CDK9MEN1MAPTKMT2A | |
| SCHEMBL6956508 | 0.88 | CCNT1 (0.42) | CCNT1CDK9ALDH1A1CDK2CCNA2 | |
| SCHEMBL7500940 | 0.87 | CCNT1 (0.46) | CCNT1CDK9MEN1KMT2ACDK2 | |
| SCHEMBL6956384 | 0.86 | CCNT1 (0.46) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL6953634 | 0.86 | CCNT1 (0.38) | CCNT1CDK9MEN1MAPTKMT2A | |
| SCHEMBL6953629 | 0.86 | CCNT1 (0.38) | CCNT1CDK9MEN1MAPTKMT2A | |
| SCHEMBL6952814 | 0.85 | CCNT1 (0.39) | CCNT1CDK9MEN1KMT2ACDK2 | |
| SCHEMBL6947835 | 0.84 | CCNT1 (0.44) | CCNT1CDK9MAPTCDK2CCNA2 | |
| SCHEMBL7508601 | 0.83 | CCNT1 (0.47) | CCNT1CDK9CDK2CCNA2 | |
| SCHEMBL6949359 | 0.83 | GSK3B (0.40) | CCNT1CDK9CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224181-B1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2003-12-03 | — | — | EP | claimed |
| US-6559164-B1 | These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. | HOFFMANN-LA ROCHE INC. | 2003-05-06 | — | — | US | claimed |
| EP-1224181-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | claimed |
| WO-2001027106-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | claimed |
| EP-1224181-B1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2003-12-03 | — | — | EP | disclosed |
| US-6559164-B1 | These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. | HOFFMANN-LA ROCHE INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1224181-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027106-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |